Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lixisenatide Main Meal vs Breakfast in T2DM
NCT01517412Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2012
- Primary completion
- May 2013
- Modality
- Peptides
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of lixisenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Change in Glycosylated Hemoglobin (HbA1c) from Baseline to Week 24. Started Feb 2012; status: completed.
02
Drugs
lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01517412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01517412.